Roivant Sciences Ltd

8. Okt. 2026, 20:07 UTC

Roivant Sciences Ltd shares declined amid negative sentiment from parent company Immunovant following caution from H.C. Wainwright regarding IMVT-1402's mid-stage study.

7. Okt. 2026, 22:02 UTC

Roivant Sciences Ltd saw a notable rise in after-market trading, gaining ground since Wednesday's close, despite being below its 20-day moving average.

6. Okt. 2026, 20:07 UTC

Roivant Sciences Ltd shares fell sharply, reaching a midday low and remaining significantly below their 20-day moving average.

5. Okt. 2026, 23:45 UTC

Roivant Sciences Ltd is trading slightly higher in after-market hours, following earlier gains, despite remaining below its 20-day moving average.

2. Okt. 2026, 22:02 UTC

Roivant Sciences Ltd is experiencing a significant decline in after-market trading, reaching its lowest point of the day amid unusual volatility.

1. Okt. 2026, 20:31 UTC

Roivant Sciences Ltd is trading higher in after-market hours, continuing its advance since Thursday's close, despite earlier pulling back from a session high.

30. Sept. 2026, 21:10 UTC

Roivant Sciences Ltd traded lower in after-market hours, closing at its lowest point of the day and significantly below its 20-day moving average.

29. Sept. 2026, 22:35 UTC

Roivant Sciences Ltd saw a slight decline in after-market trading, remaining near the lower end of its one-month range and below its 20-day moving average.

28. Sept. 2026, 22:01 UTC

Roivant Sciences Ltd is rising in after-market trading, advancing from a low point shortly after the market closed, though still below its 20-day moving average.

25. Sept. 2026, 21:20 UTC

Roivant Sciences Ltd saw a notable increase in after-market trading, recovering from a low point and advancing higher since Friday's close.

24. Sept. 2026, 23:55 UTC

Roivant Sciences Ltd is seeing a slight uptick in after-market hours, despite remaining roughly flat since Thursday's close and below its 20-day moving average.

23. Sept. 2026, 20:02 UTC

Roivant Sciences Ltd shares fell sharply after Immunovant discontinued IMVT-1402 development for cutaneous lupus erythematosus due to a failed proof-of-concept study.

22. Sept. 2026, 23:55 UTC

Roivant Sciences Ltd is higher in after-market trading following positive Phase 2 trial results for mosliciguat, showing significant improvements in pulmonary hypertension patients.

21. Sept. 2026, 23:51 UTC

Roivant Sciences Ltd is advancing in after-market trading, currently 3.88% above its 20-day moving average and near the upper end of its one-month range.

18. Sept. 2026, 23:10 UTC

Roivant Sciences Ltd is trading modestly higher in after-market hours, supported by broader market gains and resilient U.S. retail sales data.

17. Sept. 2026, 23:21 UTC

Roivant Sciences Ltd is seeing notable gains in after-market trading, continuing an upward trend after finishing higher for three consecutive sessions.

16. Sept. 2026, 23:11 UTC

Roivant Sciences Ltd shares rise in after-market trading following Stifel's initiation of coverage with a Buy rating and a price target of $51.00.

15. Sept. 2026, 23:03 UTC

Roivant Sciences Ltd is higher in after-market trading, aligning with the broader market's upward movement. The asset remains above its 20-day moving average.

14. Sept. 2026, 20:13 UTC

Shares of Roivant Sciences are lower in after-market hours, reflecting a notable decline since Monday's close, despite remaining above the 20-day moving average.

11. Sept. 2026, 20:13 UTC

Roivant Sciences Ltd. shares are lower in after-market trading, amid broader market concerns over potential Federal Reserve interest rate hikes following recent inflation data.

10. Sept. 2026, 23:31 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

9. Sept. 2026, 23:06 UTC

Roivant Sciences Ltd shares are higher in after-market hours, maintaining a narrow trading range since Wednesday's close and staying above the 20-day moving average.

8. Sept. 2026, 23:06 UTC

Roivant Sciences Ltd shares are lower in after-market hours despite positive Phase 2 trial results for mosliciguat targeting pulmonary hypertension.

4. Sept. 2026, 22:51 UTC

Roivant Sciences Ltd shares are lower in after-market trading, reflecting broader market declines and negative sentiment in the biotech sector.

2. Sept. 2026, 20:08 UTC

Roivant Sciences Ltd shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

1. Sept. 2026, 19:36 UTC

Roivant Sciences Ltd is trading lower amid broader market sentiment and rising oil prices. The stock remains below its 20-day moving average.

31. Aug. 2026, 22:01 UTC

Roivant Sciences Ltd shares are higher in after-hours trading, showing modest gains since Monday's close amid rising oil prices and geopolitical tensions.

29. Aug. 2026, 00:01 UTC

Roivant Sciences Ltd shares are higher in after-market hours, reflecting notable activity despite a retracement from earlier gains. No specific news was identified.

28. Aug. 2026, 23:01 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting notable activity following Friday's close, despite no specific news identified.

27. Aug. 2026, 23:02 UTC

Roivant Sciences Ltd. shares are higher in after-market trading, remaining above the 20-day moving average despite earlier fluctuations during the session.